Coreline Soft wins FDA nod for upgraded AVIEW 2.0 imaging AI

Coreline Soft has scored its 11th FDA clearance, winning 510(k) approval for AVIEW 2.0, the latest version of its AI-powered imaging platform.

Coreline said Tuesday that AVIEW 2.0 includes upgrades in integration, security, and UI/UX to enhance data extraction and communication across its product lineup.

The platform supports several clinical applications, including AVIEW CAC for detecting coronary artery calcium linked to heart disease, AVIEW COPD for identifying chronic obstructive pulmonary disease, and AVIEW LCS for lung disease screening.

With FDA approval in hand, Coreline is focusing on expanding its partnership with U.S.-based 3DR Labs, aiming to provide additional AI software. The company is also accelerating its expansion into Europe and Japan, driven by the new certification.